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Abstract: Continuous expression of the MGSA/
GROa, b, or g chemokine bestows tumor-forming
capacity to the immortalized murine melanocyte
cell line, melan-a. The mechanism for this transfor-
mation is unclear, although both autocrine and
paracrine processes are possible because melan-a
cells as well as endothelial cells express a low level
of the receptor for this ligand. To further define the
role of MGSA/GRO proteins in melanocyte transfor-
mation, two types of experiments were designed to
neutralize the biological effects of MGSA/GRO in
the transfected melan-a clones: (1) the effect of
neutralizing antiserum to MGSA/GRO proteins on
melan-a tumor growth was assessed; (2) the tumor-
forming capacity of melan-a clones expressing ELR
motif-mutated forms of MGSA/GRO with compro-
mised receptor affinity was compared to the tumor-
forming capacity of clones expressing wild-type
MGSA/GRO. These experiments revealed that SCID
mice inoculated with MGSA/GROa- or g-express-
ing melan-a cells and subsequently treated with
antiserum to the respective chemokine exhibited
decreased tumor growth. This reduction in tumor
growth was accompanied by declining angiogenic
activity in MGSA/GROg-expressing tumors. More-
over, athymic nude mice injected with melan-a cells
expressing ELR-mutant forms of MGSA/GROa ex-
hibited markedly impaired tumor-forming capacity
compared with those mice injected with melan-a
clones expressing wild-type MGSA/GRO. These data
suggest that continuous expression of MGSA/GRO
proteins may facilitate tumor growth by stimulating
the growth of microvessels into the tumor (para-
crine) and by affecting melanocyte growth (auto-
crine). J. Leukoc. Biol. 67: 53–62; 2000.
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INTRODUCTION
CXC chemokines encoding the ELR motif (ELR1) at the amino
terminus have been demonstrated to exhibit angiogenic activity
in a variety of contexts [1–7]. In contrast, those CXC chemo-
kines not containing this motif (ELR2) are angiostatic [4, 8, 9].
Angiogenic activity exhibited by ELR1 CXC chemokines can
be inhibited with antibodies to these chemokines [1, 3, 5,
10–14]. The angiogenic response to ELR1 CXC chemokines
interleukin-8 (IL-8), MGSA/GRO, or ENA-78 appears to be
mediated through the binding of these ligands to CXC chemo-
kine receptors [15, 16]. The expression of receptors for ELR1
chemokines on endothelial cells in wounded tissues and in both
endothelial cells and tumor cells in melanoma and head and
neck squamous cell carcinoma (HNSCC) tumors has been
verified [15–17].
We have previously demonstrated that overexpression of
MGSA/GRO proteins in immortalized melanocytes is associ-
ated with enhanced ability to form large colonies in soft agar
and enhanced ability to form tumors in nude mice [18, 19]. To
determine whether the tumor formation in stable clones express-
ing wild-type MGSA/GRO proteins was directly linked to
chemokine production and not the result of random clonal
selection, we designed a study in SCID mice where it is
possible to follow the effects of administration of rabbit
antibodies to the human MGSA/GRO proteins on tumor growth,
without obtaining an antigenic response to the rabbit antiserum.
Mice were inoculated with immortalized melan-a cells express-
ing MGSA/GRO proteins and either antiserum to MGSA/GRO
or normal rabbit serum (control) was administered every-other
day into the inoculation site to determine whether direct
inhibition of the chemokine would alter tumor growth. In the
SCID mouse model antiserum to MGSA/GROg almost totally
blocked tumor formation by MGSA/GROg-expressing melan-a
cells, whereas antiserum to MGSA/GROa only partially re-
tarded the tumor formation by melan-a cells expressing MGSA/
GROa. We were better able to demonstrate a direct role for
MGSA/GROa in tumor growth by following tumor formation of
melan-a clones expressing MGSA/GROa mutated in the ELR
motif, a conserved motif required for high-affinity binding to the
receptor. In this study we demonstrate that melan-a cells
expressing MGSA/GROa mutated in the ELR motif exhibit
markedly compromised ability to form tumors. To determine
whether the MGSA/GRO antibody treatment of SCID mice
reduced tumor growth by blocking the growth of new blood
Correspondence: Ann Richmond, Department of Cell Biology, Vanderbilt
University School of Medicine, Nashville, TN 37232. E-mail:
ann.richmond@mcmail. vanderbilt.edu
Received March 27, 1999; revised August 30, 1999; accepted August 31,
1999.
Journal of Leukocyte Biology Volume 67, January 2000 53
vessels into the tumor, we monitored the expression of the
endothelial cell surface marker, CD31, in frozen sections of
tumors from SCID mice. In mice where tumors developed, we
observed that reduced tumor size correlated with reduced CD31
immunoreactivity. These data suggest that MGSA/GRO pro-
teins affect tumor growth through both autocrine and paracrine
mechanisms.
METHODS
Design of expression vector
for MGSA/GRO proteins
A portion (550 bp) of the MGSA/GROa cDNA including the entire open
reading frame was subcloned into pALTER and mutagenesis was performed
according to standard protocols to produce MGSA/GROa with the following
mutations: E6A, L7A, R8A, and ELR/AAA. Mutated sequences including this
entire open reading frame were subsequently subcloned into the pRC/CMV
expression vector and plasmid DNA was transfected into immortalized melan-a
cells that were the kind gift of Dorthea Bennett. Stably transfected clones were
selected for neomycin resistance and maintained in selective medium, as
previously described [18]. Levels of mutated MGSA/GRO released into the
culture medium were quantitated by enzyme-linked immunosorbent assay
(ELISA) with the use of the Quantikine kit from R & D Systems. Conditioned
medium was collected from confluent cultures after 48 h of conditioning in
medium containing serum. The level of expression of mutant MGSA/GRO was
equivalent to that of the melan-a clone expressing wild-type (WT) MGSA/
GROa (WT, 0.78 ng/mL; E6A, 0.89 ng/mL; L7A, 0.70 ng/mL; R8A, 1.01
ng/mL; AAA, 1.11 ng/mL).
Tumorigenesis models
Melan-a clones selected to express MGSA/GROa, MGSA/GROa with muta-
tions in the ELR motif (E6A, L7A, R8A, and ELR/AAA), or the neomycin-
selectable marker alone (V1) were injected into female nude mice (5 3 106 cells
per mouse) as previously described with an n of 10 mice per cell type [18].
Tumor formation was monitored over a period of 8 months.
Melan-a clones previously selected to express MGSA/GROa, b, g or the
neomycin selection marker alone [19] were injected into SCID mice. Cells (5 3
106) from clones g 3–14 expressing MGSA/GROg, mel-a-6 expressing
MGSA/GROa, or V1 or V4 clones expressing the neomycin selection marker
alone, were injected subcutaneously into the interscapular region of 6-week-old
female SCID mice, with an n of 12 mice per clone type. At the time of
inoculation of the MGSA/GROa or MGSA/GROg expressing melan-a clones,
mice were also injected with decomplemented neutralizing antiserum to
MGSA/GROa or MGSA/GROg, respectively, or NRS. For each group, six of the
mice were injected with 500 µL of NRS and the other six mice were injected
with 500 µL of antiserum to MGSA/GROa or g, depending on the form of
MGSA/GRO expressed by the transfected clone. Injections were continued
every-other day over the course of several weeks, until tumor size reached an
approximate diameter of 1–1.5 cm. Mice receiving melan-a cells expressing the
neomycin selection marker alone (vector controls) did not receive injections of
serum or antiserum. When palpable tumors developed, the tumor volume was
estimated by measuring the diameter of the tumors on a weekly basis. When any
of the tumors in the group reached a diameter of 2.5 cm3, all the mice in the
group were killed, the tumors were resected, and the tumor volumes were
measured by water displacement. Tumors were then divided into aliquots for (1)
fixation, embedding, sectioning, and histological evaluation; (2) ELISA determi-
nation of chemokine expression; and (3) analysis of frozen sections for CD31
immunodetection of endothelial cells.
Western blot analysis of Ras protein
in MGSA/GRO-expressing melan-a clones
Western blots were performed on lysates of MGSA/GROa, b, g expressing
melan-a clones to detect the expression of Ras proteins using protocols
developed by Santa Cruz. The pan-Ras antibody that detects H-Ras, K-Ras,
and N-Ras (Oncogene Research Products) was used at a 1:3000 dilution in
TBS-T buffer with 5% dry milk for 12–16 h at 4°C. The membrane was then
incubated in a 1:3000 dilution of the anti-mouse antibody conjugated with
horseradish peroxidase (Boehringer Mannheim Corp.) in TBS-T buffer with 5%
dry milk for 1 h at room temperature. The protein bands were detected with the
enhanced chemiluminescence system (Amersham Pharmacia Biotech) accord-
ing to the manufacturer’s instructions. The density of the bands on the
developed blot was quantitated and plotted. The blot was performed three times
with similar results each time.
AP-1 transient transfection assays
AP-1 luciferase reporter gene constructs were prepared by inserting two copies
of the AP-1 consensus DNA binding sequence into the pGL-3 promoter vector
(Promega). Semiconfluent cultures (5 3 105 cells in 30-mm dishes) of mel-a
cells expressing MGSA/GROa, b, or g were transiently co-transfected with 2.5
µg pSV-b-Gal control vector (Promega) and 2.5 µg AP-1 luciferase reporter
gene with or without 5 µg of a dominant-negative Ras (DN-Ras) expression
construct using the calcium phosphate technique. Three hours later, the cells
were glycerol shocked for 3 min. The cells were washed twice with complete
medium, and then incubated with complete medium at 37°C/5% CO2. Two days
later, the cells were washed with cold phosphate-buffered saline (PBS) and
lysed in 13 reporter lysis buffer (Promega) for 15 min at room temperature, and
the lysate was cleared by centrifugation. The luciferase and b-Gal activity were
measured according to standard protocols (Promega) using a Monolight 2010
luminometer (Analytical Luminescence Laboratory).
Immunodetection of CD31 staining, mCXCR2,
and the CD16 natural killer (NK) marker
in tumor sections
Paraformaldehyde-fixed tissues were sectioned and processed for staining for
mCXCR2 using antibody to mCXCR2 from Santa Cruz Biologicals (1:200
dilution). CD16 antibodies were purchased from PharMingen (1:200 dilution).
Frozen sections of tumors were fixed in cold acetone and stained for CD31 using
the antibody kindly provided by Alberto Montovani, which is also available
through PharMingen [20]. Our standard protocols were used with this rat
antibody for indirect immunohistochemical detection using the Vector Labora-
tories ABC Rat IgG kit. The substrate used for the peroxidase-linked
avidin-biotin complex was 3-amino-9-ethylcarbazole (AEC) from Vector Labo-
ratories (Burlingame, CA). Slides were counterstained with Mayer’s hematoxy-
lin, dehydrated, and mounted with aqueous immu-mount (Shandon Inc.,
Pittsburgh, PA). Quantitation was by morphometric scanning using protocols
developed and published previously [21].
Corneal micropocket/angiogenesis assay
The ability of extracts from tumors expressing chemokines to stimulate
angiogenesis in the avascular cornea of F344 rat eyes was assayed according to
established procedures [1, 22, 23]. Tumor samples were ground and sonicated,
and then a 100-µL aliquot was combined from each of six tumors arising in
either the NRS-treated or antiserum-treated SCID mice to yield a combined
sample of 600 µL from each group. The MGSA/GRO antiserum-treated group of
tumors had only two tumors for analysis so 300 µL from each of these tumors
was combined to produce the 600-µL sample. Specimens were concentrated by
Speed-Vac, reconstituted in 50 µL of sterile water, and total protein was
measured. Samples were adjusted for equal amounts of total protein, and pellets
were made for analysis of the pooled extract in the corneal micropocket assay.
ELISA assay
Levels of immunoreactive MGSA/GROa and g were determined using a
modified double-ligand ELISA according to procedures previously described
[22, 24]. ELISA assays were also performed for human MGSA/GRO a and g,
murine macrophage inflammatory protein-2 (MIP-2), murine KC, murine
interferon-g (IFN-g), and murine IL-12 and IL-13 with the R & D Systems
Quantikine assay. Aliquots of conditioned medium (50 µL) from cultured
melan-a cells or aliquots of tumor tissue sonicated in lysis buffer were analyzed
in 96-well microtiter plates coated with rabbit anti-chemokine antibodies
according to our established procedures. Data from tumors are reported in
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picograms per milligram protein. Protein determinations were by the Bio-Rad
protein assay kit.
MGSA/GRO receptor expression in melan-a cells
Confluent cultures of melan-a cells expressing the neo vector alone, MGSA/
GROa (mel-a-6), MGSA/GROb (b2–19), and MGSA/GROg (g3–14) were
assayed for 125I-MGSAa binding as previously described. Nonspecific binding
was monitored by determining the binding of radiolabeled ligand in the
presence of 100-fold excess cold ligand. Receptor expression was also
monitored by immunocytochemistry on cultured melan-a clones expressing the
various forms of MGSA/GRO and by immunohistochemistry of tissue sections
of tumors that arose in nude or SCID mice. The Santa Cruz antibody to CXCR2
was used as the primary antibody in combination with the Vectastain ABC
immunostaining protocols and kits.
RESULTS
Effect of antiserum to MGSA/GRO on tumor
growth of MGSA/GROa- or g-expressing clones
Control SCID mice inoculated with melan-a clones expressing
MGSA/GROa or g and injected with NRS developed palpable
tumors between 44 and 59 days after injection of cells.
MGSA/GROg-expressing tumors grew rapidly from a mean
tumor diameter of 0.65 cm on day 59 to 1.67 cm by day 77
(tumor volume measurement by fluid displacement, 0.62 cm3).
In contrast, only three mice in the group injected in the same
manner with antiserum to MGSA/GROg developed tumors and
those three tumors remained very small, with a mean volume for
the three tumors of 0.15 cm3 (0.04 cm3 by micrometer
calculation) and a mean diameter of 0.1 cm (Fig. 1). Tumor
sizes were significantly different (P , 0.05) using a two-sample
t test assuming unequal variances. When antiserum injections
were stopped, these SCID mice developed tumors that grew
rapidly, with a growth rate comparable to that of the mice
receiving normal rabbit serum (NRS) injections (data not
shown).
Mice injected with melan-a cells producing MGSA/GROa
developed palpable tumors by day 45. All six of the mice
receiving injections of NRS every-other day developed tumors
and these tumors grew to a mean tumor diameter of 1.58 cm, or
a tumor volume as measured by fluid displacement of 1.1 cm3
by 59 days. For the SCID mice inoculated with MGSA/GROa-
expressing melan-a cells and injected with antiserum to
MGSA/GROa, five of the six mice developed tumors and these
tumors grew more slowly than in the mice injected every-other
day with NRS. The antibody-treated tumors reached a mean
diameter of only 1.1 cm, or a volume of 0.75 cm3 based on fluid
displacement (1.05 cm3 by micrometer calculation), by 59 days
after the initial inoculation into the mice (Fig. 1). The P value
for differences in mean tumor size between NRS and antibody
treatment for MGSA/GROa-expressing tumors did not achieve
statistical significance (P 5 0.103).
Effect of mutation of the ELR motif
on MGSA/GRO induction of tumor formation
Because the growth of MGSA/GROa-expressing tumors was not
fully inhibited by antibody to this chemokine, a second strategy
was developed to neutralize the activity of this ligand. We
Fig. 1. Effect of antiserum to MGSA/GROa or MGSA/GROg on the growth of
melan-a tumors in SCID mice. Melan-a cells (5 3 106) expressing MGSA/
GROg (A) or MGSA/GROa (B) were injected into 12 young female SCID mice.
(A) Mice from each group (expressing MGSA/GROa or g) were injected
every-other day with decomplemented blocking antiserum to these respective
chemokines or with heat-inactivated normal rabbit serum. We compared the
mean tumor diameter as determined by micrometer measurement in the group
injected with antibodies (Ab) to MGSA/GRO or to that of the group injected
with normal rabbit serum (NRS). Three mice of the six treated with the
antiserum to the MGSA/GROg slowly developed very small tumors (over 2.5
months; final mean tumor diameter ranged from 0.7 to 0.2 cm for the three out of
six mice that developed tumors), whereas those six mice treated with NRS
quickly developed very large tumors by 8 weeks after the initial injection of
melan-a cells expressing MGSA/GROa (final tumor diameters ranged from 2.3
to 1 cm). (B) For 8.5 weeks antiserum to MGSA/GROa (0.5 mL) or NRS (0.5
mL) was injected every-other day into SCID mice inoculated with MGSA/GROa-
expressing melan-a cells (clone mel-a-6). The diameter of the tumors was
monitored weekly by micrometer measurement. The MGSA/GROa-expressing
cells made tumors in five out of six mice injected with antibody to MGSA/
GROa (final tumor diameters ranged from 2.0 to 0.8 cm for the five out of six
mice developing tumors) while tumors arose in all six of the mice injected with
NRS (final tumor diameters ranged from 2.5 to 1.0 cm).
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produced ELR motif mutations in MGSA/GROa to compromise
the high-affinity binding of this chemokine to its receptor,
CXCR2. Stable melan-a clones expressing four different muta-
tions in the ELR motif were established: E6A, L7A, R8A, and
ELR/AAA. Mice injected with melan-a cells expressing mutant
(ELR2) ELR-MGSA/GROa exhibited a marked reduction in
tumor formation compared with those expressing wild-type
(ELR1) MGSA/GROa (Table 1). No tumors formed in the nude
mice injected with the E6A mutant clone. Approximately 5.5
months after injection, only 2–4 of the 10 mice injected with
cells expressing the L7A or R8A mutations, respectively,
formed tumors. Much later (7.5–8 months after cell inocula-
tion), small nodules (2–10 mm) had begun to form on mice
injected with the clones expressing these ELR2 mutant forms of
MGSA/GROa. In general, the tumors that formed in mice
expressing ELR motif mutant forms of MGSA/GROa did not
develop until 5–8 months after injection of cells, whereas mice
injected with melan-a cells expressing wild-type MGSA/GROa
formed tumors within 2.5 months after injection (see Table 1).
The incidence of tumor formation for the melan-a cells
expressing ELR/AAA mutant MGSA/GROa was similar to that
of melan-a cells expressing the neomycin-selectable marker
alone (V1). These data directly link the requirement for
MGSA/GROa activation of its receptor through an intact ELR
motif with induction of tumorigenesis.
Receptor expression in melan-a cells
and in tumors arising in mice injected
with MGSA/GRO-expressing melan-a cells
Ligand binding assays on melan-a cells expressing MGSA/
GROa, b, g, or neo vector controls using 125I-MGSA revealed
comparable specific binding for V1 control, MGSA/GROa, b,
and g expressing clones (1477, 1575, 1717, 1369 cpm,
respectively). Specific binding was determined in triplicate
after subtracting the counts per minute bound in the presence of
100-fold excess cold ligand. We estimate that this represents
approximately 10,000 binding sites per cell.
Immunostaining of the cells in the growing tumor revealed
that a subpopulation of cells within the tumor stained positively
with antibody to CXCR2 (Fig. 2, A–C). However, the majority
of the cells within the tumors did not exhibit mCXCR2
immunoreactivity. Moreover, blood vessels within the tumor
reacted strongly with mCXCR2 antibody, suggesting that the
secreted MGSA/GRO available from the melan-a cells could
cause these endothelial cells to induce an angiogenic response
(Fig. 2D). These data suggest that as the tumor forms there may
be both autocrine and paracrine roles for MGSA/GRO stimula-
tion of tumor growth.
Histology of tumors and detection
of inflammatory infiltrate or NK cells
To determine whether the antibody treatment of the tumors
resulted in binding of antibody to NK cells through the Fc
receptor, and potential activation of these cells to enhance cell
killing, we examined the histology of the H & E-stained tumors
and attempted to localize NK cells within the tumors through
the use of specific markers for NK cells (CD16). Histological
examination of the tumors that arose in the MGSA/GROa or g
TABLE 1. Effect of Mutation of the ELR Motif of the MGSA/GRO










Mouse 1 3.5 5 months 1.0 ml
Mouse 2 5.5 7.5 months 2.5 ml
Mouse 3 5.5 8 months 3.5 ml
Mouse 4 5.5 8 months 3.0 ml
Mouse 5 6.5 10 mm
Mouse 6 7.5 6–7 mm
Mouse 7 8 4–5 mm
Mouse 8 8.5 2–3 mm
Mouse 9 8.5 2–3 mm
Mouse 10 8.5 2–3 mm
MUTANT R8A
Mouse 1 4.5 6 months 1.3 ml
Mouse 2 5 7.5 months 2.5 ml
Mouse 3 5.5 8 months 2.0 ml
Mouse 4 7.5 6–8 mm
Mouse 5 7.5 6–8 mm
Mouse 6 7.5 6–8 mm
Mouse 7 7.5 6–8 mm
Mouse 8 No tumor
formed
Mouse 9 No tumor
formed
Mouse 10 No tumor
formed
MUTANT AAA
Mouse 1 5.5 7.5 months 3.0 ml
Mouse 2 5.5 7.5 months 2.5 ml
Mouse 3 8.5 2–3 mm
Mouse 4 No tumor
formed
Mouse 5 No tumor
formed
Mouse 6 No tumor
formed
Mouse 7 No tumor
formed
Mouse 8 No tumor
formed
Mouse 9 No tumor
formed
Mouse 10 No tumor
formed
WT MGSA
Mouse 1 1.5 2.5 months 5.0 ml
Mouse 2 1.5 2.5 months 2.5 ml
Mouse 3 1.5 2.5 months 2.0 ml
Mouse 4 2 3 months 2.5 ml
Mouse 5 2 3 months 2.5 ml
Mouse 6 2 3 months 2.0 ml
Mouse 7 2 3 months 2.2 ml
Mouse 8 2.5 3 months 1.5 ml
Mouse 9 8 mm
Mouse 10 4 mm
Mouse 11 5 mm





Melan-a cells were transfected with MGSA/GROa expression vectors exhib-
iting the following mutations in the ELR motif: E/A, L/A, R/A, or ELR/AAA.
Stable clones were selected based on neomycin resistance, expanded, expres-
sion of mutant protein was verified by ELISA assay, and 5 3 106 cells were in-
jected from each clone into female nude mice of approximately 8 weeks of age.
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antibody-treated group or the NRS-treated group did not reveal
the presence of inflammatory infiltrate or NK cells within the
tumors (Fig. 2, E–H).
Tumor vascularity assessment
To determine whether antiserum inhibition of tumor growth was
due in part to inhibition of angiogenesis, we examined the
vascularity of antiserum-treated tumors with the use of an
immunohistochemical marker for endothelial cells, CD31 [25]
(Fig. 3). Although there are visual differences in the extent of
vascularity as assessed by CD31 immunostaining, quantitation
of the total immunoreactivity using 15 high-magnification
microscrope fields revealed little difference in the CD31
immunodetection in the antibody-treated group of tumors
compared with the NRS-treated tumors (Table 2). The MGSA/
GROg tumors treated with NRS had a mean staining volume
over the tumor of 2208 6 1506, whereas the antiserum-treated
group from the two small tumors that arose from the six mice
treated gave a mean staining volume of 1345 (range 979–1710)
over the tumors (P 5 0.28). Similarly, for the tumors expressing
Fig. 2. Immunolocalization of mCXCR2
and histology of the melan-a tumors. Tu-
mors that arose in SCID mice injected with
melan-a cells expressing MGSA/GROg
were fixed in paraformaldehyde, embed-
ded in paraffin, sectioned, and stained
with antibody to mCXCR2 (Santa Cruz
Biotechnology, Inc.) using the ABC Elite
kit from Vector Laboratories, with a sub-
strate of aminoethyl carbazole for the
peroxidase, which produces a red staining
indicative of the presence of the antigen,
mCXCR2. (A) Note the presence of a
subset of non-melanotic tumor cells that
stain strongly for immunoreactive mCXCR2
(original magnification, 3200). (B) The
presence of imunoreactive mCXCR2 tu-
mor cells interspersed among highly pig-
mented tumor cells is shown (original
magnification 3200). (C) At higher power
(original magnification 31000) the pres-
ence of CXCR2 immunoreactive spindle-
shaped tumor cells in the area of a number
of highly pigmented tumor cells is shown.
(D) The presence of immunoreactive
mCXCR2 in the endothelial cells of a
blood vessel in the tumor that formed after
injection of melan-a cells expressing
MGSA/GROg (original magnification
31000). Additional capillaries in cross
section also exhibit immunoreactivity for
the mCXCR2. (E, F) The H & E staining
of the MGSA/GROg-expressing tumors
treated with NRS (E) or antiserum to
MGSA/GROg is shown (F) (original mag-
nification 31000). (G, H) The H & E
staining of the MGSA/GROa-expressing
tumors treated with NRS (G) or antiserum
to MGSA/GROa is shown (H) (original
magnification 31000). Note the typical
lack of leukocytic infiltration in these
tumors.
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MGSA/GROa, the mean CD31 staining volume over the tumors
was 4462 6 955 from the NRS-treated serum compared with
6168 6 1361 (P 5 0.05) for the group of tumors arising in the
MGSA/GROa antiserum-treated group. Although the raw data
indicated that the fields examined from the MGSA/GROg
antiserum-treated group had highly similar areas of CD31
staining, closer inspection by multiplying the total tumor
volume by the area of CD31-positive vessels within tumors
revealed a trend toward reduced vascularity per tumor in the
antiserum-treated group compared with the NRS treatment
group (vascularity index: NRS-treated MGSA/GROg tumors,
1542 6 1558; antibody-treated MGSA/GROg tumors, 183 6
12, P 5 0.08). A difference was also observed in the vascularity
index for the MGSA/GROa-expressing tumors: NRS-treated
tumors, 6016 6 4827; anti-serum-treated tumors, 3922 6
4360. However, differences in these means did not show
statistical significance based on the two-sample t test. For
tumors that arose from mel-a cells expressing both MGSA/
GROa and MGSA/GROg, there were no significant differences
in the distribution of the blood vessels with NRS or chemokine
antiserum treatment.
Angiogenic response to tumor extracts from mice
treated with NRS versus antiserum
to MGSA/GRO
When extracts of the tumor lysates were analyzed for angio-
genic activity in the corneal micropocket/angiogenesis assay,
we observed that the MGSA/GROa and MGSA/GROg tumors
arising in the NRS-treated group were all able to produce a
strong angiogenic response, 4/4 positive for the MGSA/GROa
tumor extracts and 3/3 positive for the MGSA/GROg tumors
(Table 3). In contrast, the tumors arising in the antiserum-
treated animals did not yield a positive angiogenic response
(3/3 negative for the MGSA/GROg tumors and 4/4 negative for
the MGSA/GROa-expressing tumors). Thus, the antibody treat-
ment neutralized the tumor angiogenesis.
ELISA determination of ELR1 versus ELR2
chemokines: quantitation of the levels
of MGSA/GRO proteins expressed
in the tumors that formed
To determine whether the growth of the MGSA/GROa- and
MGSA/GROg-expressing tumors was differentially inhibited
by antiserum to the respective chemokine because the a-ex-
pressing tumors produced higher levels of ELR1 chemokine,
we allowed tumors to develop in SCID mice without antiserum
injections, removed the tumors at the same time, then moni-
tored the tumor levels of MGSA/GROa, MGSA/GROg, KC, and
MIP-2 by ELISA. The results from this experiment revealed
considerable variation in the level of expression of chemokine
from tumor to tumor (Table 4). The MGSA/GROa tumors
produced a mean MGSA/GROa of 432 pg/mg protein (range
20–1120); the MGSA/GROg tumors produced a mean of only
30 pg of MGSA/GRO/mg of protein (range 9–116; P 5 0.001).
There was a trend toward higher expression of KC and MIP-2 in
the MGSA/GROa-expressing tumors, compared with MGSA/
GROg-expressing tumors: MGSA/GROg tumor MIP-2 levels
were 45 pg/mg protein (range 4–210); KC levels were 20 pg/mg
Fig. 3. Immunohistochemical staining of tumor-associated blood vessels as visualized by CD31 antisera. (A, B) Heavily pigmented MGSA/GRO tumors: A, received
treatment with normal rabbit serum and shows robust in-growth of blood vessels; B, received treatment with MGSA/GRO antisera and shows scant numbers of blood
vessels. (C, D) Non-pigmented MGSA/GRO tumors: panel C shows moderate neovascularization after treatment with normal rabbit serum; panel D shows little
evidence of neovascularization after treatment with MGSA/GRO antisera.
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protein (range 3–117); for MGSA/GROa tumors the MIP-2
levels were 197 pg/mg protein (range 24–321), and KC levels
were 59 pg/mg protein (range 9–148). It has been demonstrated
previously that MGSA/GRO can augment the expression of its
own mRNA in cultured endothelial cells [34]. We postulate that
expression of MGSA/GRO by the injected melan-a cells can
also activate expression of KC and MIP-2 in the endothelial
cells of the tumors and thus enhance chemokine levels. When
the total mean expression of MGSA/GRO, MIP-2, and KC are
totaled for the a- and g-expressing tumors from the experiment
using five mice to calculate the mean chemokine expression,
there is a trend toward higher expression of these CXC
chemokines in the MGSA/GROa-expressing tumors compared
with the MGSA/GROg-expressing tumors, although the ranges
of expression overlap between these two groups: MGSA/GROa-
expressing clone, 95 pg/mg protein; MGSA/GROg-expressing
clone, 688 pg/mg protein, P , 0.001 (Table 3). A similar trend
was observed using the R & D Quantikine ELISA kit. Because
MGSA/GROa, MGSA/GROg, MIP-2, and KC all bind and
activate the same receptor, these total differences in ligands for
CXCR2 may have a significant biological impact on the growth
of tumors in the mice.
To determine whether the differences in the tumor growth
and antibody inhibition between the MGSA/GROa and g-ex-
pressing clones were due to variation in the production of
cytokines that might inhibit tumor growth or alter the recruit-
ment of NK cells or other leukocytes, we performed ELISA
assays for key cytokines on conditioned medium from these
clones. The levels of IFN-g, IL-12, and IL-13 production by the
MGSA/GROa, g, and vector control melan-a clones were
examined. There was no detectable release of these cytokines
into the culture medium in any of the three melan-a clones (data
not shown). Thus differences in tumor growth between MGSA/
GROa- or g-expressing clones are not due to differential
production of these cytokines.
Differential Ras expression and AP-1 activity
in MGSA/GROa-expressing Mel-a-6 cells
compared with melan-a clones expressing
MGSA/GROb or g
We postulated that the differences in tumor growth of the
MGSA/GROa-expressing clones could be the result of the
ability of MGSA/GROa acting through CXCR2 on the melan-a
cells to induce a secondary transforming event, which would not
be sensitive to inhibition by antibody to MGSA/GROa. Be-
cause ras is often involved in melanoma tumorigenesis, we
examined the expression of Ras proteins in melan-a clones
expressing the various forms of MGSA/GRO compared with
vector controls using Western blot analysis as described in
Materials and Methods. We observed that the MGSA/GROa-
expressing clone gave a stronger expression of Ras protein,
using an antibody that would detect H, N, and K-Ras (Table 5).
This enhanced expression of Ras protein in the MGSA/GROa-
expressing clone was associated with increased AP-1 transcrip-
tional activity using an assay that involved transient transfection
with an AP-1-luciferase reporter construct, using co-transfec-
tion with b-Gal to normalize for transfection efficiency (Table
5). We examined AP-1 activity in three separate clones
expressing MGSA/GROa, three clones expressing MGSA/
GROb, and three clones expressing MGSA/GROg (data not
shown). Consistently, the MGSA/GROa-expressing clones ex-
hibited elevated AP-1 transactivation compared with the MGSA/
GROb- and g-expressing clones. These data argue that the
AP-1 activation occurs in response to MGSA/GROa expression
and is not the result of clonal variation. Moreover, transfection
TABLE 2. CD31 Immunostaining of Tumors from SCID Mice
Treated with NRS or Antiserum to MGSA/GRO








MGSA/GROg tumors with NRS
1 4222 6465 10,687 1.0 4222
2 3633 1984 7823 0.3 1089
3 1670 4285 5955 0.3 501
4 2312 2117 4229 1.1 2543
5 230 1396 1628 0.3 69
6 1186 1987 3173 0.7 830
Mean 2208 6 1506 1542 6 1558
MGSA/GROg Tumors with Ab
1 979 3335 4314 0.2 196
2 1710 1569 3279 ,0.1 171
Mean 1345 183
MGSA/GROa tumors with NRS
1 5218 2154 7372 2.5 13045
2 2768 2114 4882 0.1 277
3 5160 2542 7702 0.7 3612
4 5126 1096 6222 1.5 9333
5 4483 984 5467 1.4 7654
6 4019 1416 5435 0.4 2174
Mean 4462 6 955 6016 6 4827
MGSA/GROa tumors with AB
1 5456 2805 8261 1.0 5456
2 4955 2050 7005 2.2 10901
3 8480 1836 10,316 ,.1 848
4 5908 2649 8557 ,.1 591
5 6043 2248 8291 0.3 1812
Mean 6168 6 1361 3922 6 4360
Tumor vascularity was assessed by staining endothelial cells in acetone-fixed
frozen sections of tumor with rat antibody to CD31 followed by Vector
Laboratories ABC kit. Morphometric scanning was used for quantitation of the
total immunoreactivity over 15 fields of tumor or fat and dermis. The staining
index was determined by multiplying the relative CD31 staining over the tumor
by the tumor volume, as determined by fluid displacement of the dissected
tumor.
TABLE 3. Angiogenic Activity in Tumor Lysates From SCID Mice
Treated With NRS or MGSA/GRO Antiserum
MGSA/GROg tumors with NRS 3/3 eyes positive
MGSA/GROg tumors with MGSA/GRO antibody 3/3 eyes negative
MGSA/GROa tumors with NRS 4/4 eyes positive
MGSA/GROa tumors with MGSA/GRO antibody 4/4 eyes negative
Tumors from antiserum or NRS-treated SCID mice were dissected, sectioned,
ground, and sonicated in buffer using previously published protocols [22, 23].
One hundred-microliter aliquots were combined to produce a sample of 600 µL
from each group, samples were concentrated and reconstituted in 50 µL of
sterile water, total protein was measured, and the hydron pellets were made for
analysis through the use of the corneal micropocket assay according to standard
procedures. Six rat eyes were studied from the MGSA/GROg tumors and eight
were studied from the MGSA/GROa treatment group.
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of a dominant-negative Ras construct along with the AP-1
reporter demonstrated that elimination of the endogenous Ras
activity blocked the elevation in endogenous AP-1 activity in
the MGSA/GROa-expressing mel-a-6 clone (Table 5). These
data suggest that constitutive expression of MGSA/GROa can
have secondary effects on gene expression that contribute to the
stronger transforming effect of MGSA/GROa compared with
MGSA/GROb or g.
DISCUSSION
The role of CXC chemokines in angiogenesis [1, 7, 23] and
wound healing [26] has been recently clarified. Squamous cell
carcinoma and non-small-cell lung tumors express ELR1
chemokines and the angiogenic activity in these tumors can be
inhibited with antibodies to ELR1 chemokines such as IL-8 [5,
11, 27, 28]. The elaboration of chemokines by tumor cells has
been clearly established, and it has been postulated that release
of chemokines from tumor cells expressing receptors for the
ELR motif positive chemokines might also facilitate tumor
growth through an autocrine mechanism [4, 5, 9, 11, 27,
29–36]. In work reported here, we demonstrate that immortal-
ized melanocytes expressing MGSA/GROa mutated in the ELR
motif are compromised with regard to tumor-forming capacity.
Moreover, we demonstrate that stable clones of melanocytes
releasing the transgene product MGSA/GROa or MGSA/GROg
form tumors in SCID mice and that treatment of the mice with
antiserum to MGSA/GRO from the time of the initial inocula-
tion with melanocytes expressing these chemokines results in a
significant reduction in tumor growth. The murine CXCR2
receptor [37] is clearly visible on a population of the tumor cells
and in the blood vessels within the tumor, being displayed
prominently in the endothelial cells, pericytes, and smooth
muscle cells of the vessels. Thus, it is conceivable that
MGSA/GRO activation of melan-a cells and blood vessel
growth could involve CXCR2. Analysis of the ability of the
tumor extracts from the antibody-treated mice revealed little
angiogenic activity in these tumors in comparison to the
NRS-treated mice where a full angiogenic response was
observed [19]. Because the tumors showed prominent vascular-
ity, it is apparent that some tumor-associated angiogenesis did
take place during the development of the tumor, although this
process had apparently been suppressed by the time the tumor
was extracted and the CMA was performed. Although the ELR1
murine CXC chemokines, KC and MIP-2, were present in the
tumor extracts, the angiogenic potential of these ligands must
have been blocked by angiostatic substances within the tumor,
based on the 100% inhibition of the angiogenic response in the
presence of antibodies to MGSA/GROa or g. A recent report
from Bergers et al. shows that CD31 staining/cm3 of tumor
remains equivalent in tumors treated with endostatin and
angiostatin, whereas tumor volume shrinks due to apoptosis of
endothelial cells [39].
The antiserum to MGSA/GROg almost totally blocked tumor
growth in vivo, based on reduced tumor formation and reduced
tumor volume. These antibodies also inhibited angiogenesis by
73 or 89%, based on CD31 staining. We did not observe the
same quantitative antibody inhibition for clones expressing
MGSA/GROa compared with MGSA/GROg. We postulate
three possible reasons for these differences. (1) Based on the
ELISA results summarized in Table 4, there may be a
contribution from the somewhat higher combined level of
expression of MGSA/GRO, MIP-2, and KC in the MGSA/GROa-
expressing cells (688 pg/mg protein) compared with the MGSA/
GROg-expressing cells (95 pg/mg protein). However, the in
vitro expression of chemokines was similar for the a- and
g-expressing cells [19]. Because the angiogenic activity of the
tumor lysates was totally eliminated in the antiserum-treated
tumor group (Table 3), these data suggest that the antiserum to
MGSA/GROa was present at sufficiently high levels to neutral-
ize the angiogenic activity of this chemokine, even if it were
TABLE 4. Quantitation of MGSA/GRO, KC, and MIP-2 Levels in Tumors that Arose on the SCID Mice Innoculated
with MGSA/GROa or MGSA/GROg Expressing Melan-a Cells
Tumor line MGSA/GROa, pg/mg protein MGSA/GROg, pg/mg protein KC, pg/mg protein MIP-2, pg/mg protein Total
MGSA/GROg 30 (9–116) 20 (3–117) 45 (4–210) 95
MGSA/GROa 432 (20–1120) 59 (9–148) 197 (24–321) 688
ELISA assays and protein determinations were performed on sonicated tumor tissue using procedures previously described [22, 24]. Tumors that formed in
antibody treatment and NRS treatment groups were tested multiple times and the mean values for each treatment group were analyzed. Mean determinations are
shown; ranges of the determinations are shown in parentheses.
TABLE 5. Levels of Ras Protein and AP-1 Transactivating Activity
Clone Vector MGSA/GROb MGSA/GROg MGSA/GROa
Ras protein expression level (fold) 1 4.15 6 0.65 3.25 6 0.05 7.00 6 0.90
Basal AP-1 transactivation (fold) 1 1.12 6 0.32 2.10 6 0.18 3.16 6 0.45
Dominant-negative Ras inhibits AP-1 transactivation 0.54 6 0.10 0.48 6 0.01 0.43 6 0.12
The level of Ras protein and AP-1 transactivating activity were monitored by Western blot and by luciferase activity in the MGSA/GROa-, b-, and g-expressing
melan-a clones as described in Materials and Methods. The luciferase and b-Gal activities were measured 48 h after transfection. Transfection efficiency was
normalized by comparing AP-1 luciferase activity to b-galactosidase activity. The data are reported as mean 6 SEM fold induction (the relative luciferase activity of
MGSA/GROa, b, g divided by the relative luciferase activity of the vector) from three independent experiments. In experiments involving dominant-negative Ras
transfection, the results are reported as mean fold inhibition 6 SEM (the relative luciferase activity of dominant-negative form of M-Ras divided by the relative
luciferase activity of pBK-CMV vector) from three independent experiments. Co-transfection of the dominant negative Ras expression construct with the AP-1
luciferase reporter construct resulted in a marked reduction in endogenous AP-1 reporter activity.
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expressed at higher levels. Specific ELISAs for murine mig and
IP-10 are not available, so we were unable to accurately access
the levels of these angiostatic chemokines in the tumors that
developed. (2) Alternatively, there may also be innate differ-
ences in the biological activity of MGSA/GROa versus MGSA/
GROg. Here we show that melan-a cells expressing MGSA/
GROa with mutation in the ELR motif formed tumors much
more slowly than melan-a cells expressing wild-type MGSA/
GRO. These data demonstrate that compromising the biological
activity of the MGSA/GROa ligand by altering the affinity for
the receptor [39] markedly reduces tumor growth. Although it
has been previously demonstrated that ELR mutant forms of
CXC chemokines exhibit loss of angiogenic activity [22], there
has been no prior demonstration that these mutations affect
tumor growth. (3) Finally, there may be quantitative differences
in the cellular response to MGSA/GROa compared with g,
which affects gene expression, and this may render the cells
less responsive to antibody inhibition. We show here that there
is enhanced expression of Ras protein and enhanced AP-1
transcriptional activity. These events could contribute to second-
ary effects on gene transcription, which could conceivably
contribute to the increased transforming activity of MGSA/
GROa or to the partial resistance of melan-a tumors formed by
clones expressing MGSA/GROa to growth inhibition using
antibody to the chemokine transgene product. Moreover, we
have examined differences in gene expression of the a- and
g-expressing clones using the differential display technique to
determine whether other factors might be contributing to
differences in the antibody inhibition of tumor growth between
these two MGSA/GROa- and g-expressing clones. Initial
results suggest that expression of MGSA/GROa is a stronger
inducer of expression of several genes, including Ras, than is
MGSA/GROg [Wang et al., unpublished results]. Moreover, the
differences in the Ras-dependent constitutive AP-1 transcrip-
tional activity in MGSA/GROa-expressing clones compared
with clones expressing MGSA/GROb or g or the ELR/AAA
mutant form of MGSA/GROa could lead to altered transcription
of other genes involved in melanocyte transformation. These
differences in gene expression could also contribute to the
transformed phenotype of melan-a cells and to the resistance to
antiserum inhibition of growth of the MGSA/GROa-expressing
clones.
One potential nonspecific effect of antibody injection into
SCID mice could include the activation of NK cells through the
binding of the Fc portion of the antibody to the Fc receptor on
the NK cells. Several lines of evidence suggest that this is not
the case in the model tested here. First, we did not observe
leukocytic infiltration into the developing tumors with or
without antibody injection. Second, differential activation of
NK cells could not explain the differences observed with the
treatment of developing tumors with antibody to MGSA/GROa
versus MGSA/GROg because we injected the same amount of
antiserum into mice inoculated with cells expressing both
MGSA/GROa and MGSA/GROg, yet the antiserum to MGSA/
GROg produced a greater inhibition of tumor growth.
A second potential problem with this model might be
differential expression of an inhibitory substance such as
IFN-g, IL-13, or IL-12, which could differentially affect tumor
growth in the various clones. We did not observe differences in
IFN-g expression in the conditioned medium of these cultures
(data not shown). The markedly reduced tumor burden in mice
expressing ELR mutant forms of MGSA/GROa also argues
against the possibility that differential induction of cytokine
expression by transfected bacterially produced DNA might be
responsible for the differences in tumor growth observed
between the a and g expressors. Thus, we believe that the
tumor growth is occurring in response to continuous expression
of chemokines.
In summary, we have shown here that continuous MGSA/
GRO expression may lead to enhanced melanocyte tumor
formation through autocrine stimulation of melanocyte growth,
enhancement of the growth of blood vessels to the tumor, and
induction of changes in gene expression. Continuous expres-
sion of the a, b, or g forms of MGSA/GRO in melanocytes
results in transformation, but the effects on melanocyte growth
and gene expression may vary with the form of MGSA/GRO
expressed.
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